title: TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo.
abstract: Iron chelation therapy is an effective approach to the treatment of iron overload conditions, in which iron builds up to toxic levels in the body and may cause organ damage. Treatments using deferoxamine, deferasirox and deferiprone have been introduced and despite their disadvantages, they remain the first-line therapeutics in iron chelation therapy. Our study aimed to compare the effectiveness of the iron chelation agent TLc-A, a nano chelator synthetized based on the novel nanochelating technology, with deferoxamine. We found that TLc-A reduced iron overload in Caco2 cell line more efficiently than deferoxamine. In rats with iron overload, very low concentrations of TLc-A lowered serum iron level after only three injections of the nanochelator, while deferoxamine was unable to reduce iron level after the same number of injections. Compared with deferoxamine, TLc-A significantly increased urinary iron excretion and reduced hepatic iron content. The toxicity study showed that the intraperitoneal median lethal dose for TLc-A was at least two times higher than that for deferoxamine. In conclusion, our in vitro and in vivo studies indicate that the novel nano chelator compound, TLc-A, offers superior performance in iron reduction than the commercially available and widely used deferoxamine.
authors.affiliation: Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.
authors.forename: Somayeh
authors.initials: S
authors.lastname: Kalanaky
authors.affiliation: Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.|Cancer Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
authors.forename: Maryam
authors.initials: M
authors.lastname: Hafizi
authors.affiliation: Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.
authors.forename: Sepideh
authors.initials: S
authors.lastname: Safari
authors.affiliation: Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
authors.forename: Kazem
authors.initials: K
authors.lastname: Mousavizadeh
authors.affiliation: Department of Biotechnology, College of Science, University of Tehran, Tehran, Iran.
authors.forename: Mahboubeh
authors.initials: M
authors.lastname: Kabiri
authors.affiliation: Department of Laboratory Science, Faculty of Allied Medicine, Kerman University of Medical Sciences, Kerman, Iran.
authors.forename: Alireza
authors.initials: A
authors.lastname: Farsinejad
authors.affiliation: Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran. sfakharzade@nanochelatingtechnology.com.
authors.forename: Saideh
authors.initials: S
authors.lastname: Fakharzadeh
authors.affiliation: Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran. mnazaran@nanochelatingtechnology.com.
authors.forename: Mohammad Hassan
authors.initials: MH
authors.lastname: Nazaran
mesh_terms: D000818:Animals; D018938:Caco-2 Cells; D003676:Deferoxamine / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007501:Iron / Q000378:metabolism*; D007502:Iron Chelating Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D019190:Iron Overload / Q000188:drug therapy / Q000378:metabolism*; D008099:Liver / Q000378:metabolism; D008297:Male; D053758:Nanoparticles; D036103:Nanotechnology; D017208:Rats, Wistar
chemical_list: D007502:Iron Chelating Agents; D007501:Iron; D003676:Deferoxamine
keywords: Deferoxamine; Iron overload; Nano chelator; Nanochelating Technology; TLc-A
references.citation: Int J Nanomedicine. 2014 Aug 11;9:3841-53
references.pmid: 25143732
references.citation: Prog Brain Res. 2009;180:97-108
references.pmid: 20302830
references.citation: Retina. 2008 Jun;28(6):894-9
references.pmid: 18536609
references.citation: Blood. 2003 Sep 1;102(5):1583-7
references.pmid: 12763939
references.citation: Transl Res. 2006 Aug;148(2):63-71
references.pmid: 16890146
references.citation: Vaccine. 2013 May 24;31(22):2591-7
references.pmid: 23583463
references.citation: Ann N Y Acad Sci. 2005;1054:124-35
references.pmid: 16339658
references.citation: Blood Cells Mol Dis. 2013 Oct;51(3):142-5
references.pmid: 23816436
references.citation: Hemoglobin. 2011;35(3):206-16
references.pmid: 21599433
references.citation: Traffic. 2005 Mar;6(3):199-204
references.pmid: 15702988
references.citation: Arch Dis Child. 1974 Mar;49(3):195-9
references.pmid: 4825624
references.citation: J Coll Physicians Surg Pak. 2010 Aug;20(8):551-3
references.pmid: 20688025
references.citation: FEBS Lett. 1997 Feb 17;403(2):213-9
references.pmid: 9042969
references.citation: Br J Haematol. 1995 Apr;89(4):757-61
references.pmid: 7772512
references.citation: Hemoglobin. 2008;32(6):601-7
references.pmid: 19065340
references.citation: N Engl J Med. 1994 Sep 1;331(9):574-8
references.pmid: 8047081
references.citation: Acta Haematol. 2008;120(2):123-8
references.pmid: 19018129
references.citation: Adv Ther. 2008 Aug;25(8):725-42
references.pmid: 18704280
references.citation: Ann N Y Acad Sci. 1964 Oct 7;119:758-68
references.pmid: 14219455
references.citation: Hematol Oncol Clin North Am. 2014 Aug;28(4):703-27, vi
references.pmid: 25064709
references.citation: Expert Opin Pharmacother. 2003 Oct;4(10):1763-74
references.pmid: 14521486
references.citation: Mol Pharmacol. 1997 May;51(5):842-52
references.pmid: 9145923
references.citation: Lancet. 2002 Aug 17;360(9332):516-20
references.pmid: 12241655
references.citation: Eur J Haematol. 2008 Feb;80(2):93-106
references.pmid: 18081719
references.citation: Antioxid Redox Signal. 2008 Jun;10(6):997-1030
references.pmid: 18327971
references.citation: CNS Neurol Disord Drug Targets. 2012 Feb;11(1):81-5
references.pmid: 22229318
references.citation: Blood. 1977 Sep;50(3):433-9
references.pmid: 328083
references.citation: J Control Release. 2008 Dec 18;132(3):164-70
references.pmid: 18571265
references.citation: J Glob Infect Dis. 2012 Jan;4(1):62-8
references.pmid: 22529630
references.citation: Hemoglobin. 2008;32(1-2):1-15
references.pmid: 18274978
references.citation: J Coll Physicians Surg Pak. 2011 Nov;21(11):718; author reply 718
references.pmid: 22078360
references.citation: Methods Mol Biol. 2010;610:123-44
references.pmid: 20013176
references.citation: Blood Rev. 2012 Apr;26 Suppl 1:S16-9
references.pmid: 22631036
references.citation: Apoptosis. 2015 Mar;20(3):298-309
references.pmid: 25451011
references.citation: Blood. 2007 Jun 15;109(12):5157-9
references.pmid: 17344464
references.citation: Curr Med Chem. 2009;16(5):576-90
references.pmid: 19199923
references.citation: Blood Cells Mol Dis. 2010 Oct 15;45(3):215-8
references.pmid: 20605573
references.citation: Klin Padiatr. 2007 May-Jun;219(3):158-65
references.pmid: 17525910
references.citation: Klin Monbl Augenheilkd. 1996 Jul;209(1):31-6
references.pmid: 8965474
references.citation: Expert Opin Drug Saf. 2010 Jul;9(4):633-41
references.pmid: 20553089